Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)
NCT ID: NCT00352560
Last Updated: 2010-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
44 participants
INTERVENTIONAL
2006-07-31
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling in Patients With Hypertension and Permanent Pacemakers
NCT00225667
Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence
NCT00267930
Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.
NCT00035451
Ablation Verses Anti-arrhythmic Therapy for Reducing All Hospital Episodes From Recurrent Atrial Fibrillation
NCT02459574
Intravenous Cardioversion of Atrial Fibrillation (AF) With AZD1305
NCT00915356
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Irbesartan
Tablets, Oral, 300 mg, once daily, 30 days.
B
Placebo
Tablets, Oral, 0 mg, once daily, 30 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Irbesartan
Tablets, Oral, 300 mg, once daily, 30 days.
Placebo
Tablets, Oral, 0 mg, once daily, 30 days.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Mitral valve disease
* VEF\<40%
* Myocardiopathy
* LVH
* cardiac surgery
* AF reversible
* QT c\>450
* Recent MI/stroke, severe HTN
* Requirement of ACEI/ARBs
* Coronary synd., HTA, liver disease
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Bristol-Myers Squibb
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Miguel Angel Sanchez Zamorano, MD
Role: STUDY_DIRECTOR
Medical Department, Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Madrid, , Spain
Local Institution
Madrid, , Spain
Local Institution
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CV131-235
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.